<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">03751</article-id><article-id pub-id-type="doi">10.7554/eLife.03751</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>A kinase-independent function of AKT promotes cancer cell survival</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-13967"><name><surname>Vivanco</surname><given-names>Igor</given-names></name><aff><institution content-type="dept">Human Oncology and Pathogenesis Program</institution>, <institution>Memorial Sloan-Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15803"><name><surname>Chen</surname><given-names>Zhi C</given-names></name><aff><institution content-type="dept">Human Oncology and Pathogenesis Program</institution>, <institution>Memorial Sloan-Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15804"><name><surname>Tanos</surname><given-names>Barbara</given-names></name><aff><institution content-type="dept">Cell Biology Program</institution>, <institution>Memorial Sloan-Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-22027"><name><surname>Oldrini</surname><given-names>Barbara</given-names></name><aff><institution content-type="dept">Seve Ballesteros Foundation Brain Tumor Group</institution>, <institution>Spanish National Cancer Research Centre</institution>, <addr-line><named-content content-type="city">Madrid</named-content></addr-line>, <country>Spain</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-22028"><name><surname>Hsieh</surname><given-names>Wan-Ying</given-names></name><aff><institution content-type="dept">Department of Pharmacology</institution>, <institution>Weill-Cornell Graduate School of Biomedical Sciences</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15805"><name><surname>Yannuzzi</surname><given-names>Nicolas</given-names></name><aff><institution content-type="dept">Human Oncology and Pathogenesis Program</institution>, <institution>Memorial Sloan-Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15806"><name><surname>Campos</surname><given-names>Carl</given-names></name><aff><institution content-type="dept">Human Oncology and Pathogenesis Program</institution>, <institution>Memorial Sloan-Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-15802"><name><surname>Mellinghoff</surname><given-names>Ingo K</given-names></name><aff><institution content-type="dept">Human Oncology and Pathogenesis Program</institution>, <institution>Memorial Sloan-Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country><email>mellingi@mskcc.org</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1072"><name><surname>Davis</surname><given-names>Roger</given-names></name><role>Reviewing editor</role><aff><institution>University of Massachusetts Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>31</day><month>12</month><year>2014</year></pub-date><volume>3</volume><elocation-id>e03751</elocation-id><supplementary-material><ext-link xlink:href="elife-03751-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>22</day><month>06</month><year>2014</year></date><date date-type="accepted"><day>31</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>Â© 2014, Vivanco et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Vivanco et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>The serine-threonine kinase AKT regulates proliferation and survival by phosphorylating a network of protein substrates. Here we describe a kinase-independent function of AKT. In cancer cells harboring gain-of-function alterations in MET, HER2, or Phosphatidyl-Inositol-3-Kinase (PI3-K), catalytically-inactive AKT (K179M) protected from druginduced cell death in a PH-domain dependent manner. An AKT kinase domain mutant found in human melanoma (G161V) lacked enzymatic activity in-vitro and in AKT1/AKT2 double knockout cells, but promoted growth-factor independent survival of primary human melanocytes. ATP-competitive AKT inhibitors failed to block the kinase-independent function of AKT, a liability that limits their effectiveness compared to allosteric AKT inhibitors. Our results broaden the current view of AKT function and have important implications for the development of AKT inhibitors for cancer.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></back></article>